Highlights
- A 2026 Circulation study introduces platelet olfactory receptor 2L13 (OR2L13) as a first-in-class antithrombotic target, expanding the concept of extranasal olfactory receptors into cardiovascular pharmacology.
- High-throughput screening identified six OR2L13 agonists; the lead probe, CCF0054500, inhibited platelet aggregation and α-granule secretion across agonist pathways, implying convergence on a shared downstream mechanism.
- Phosphoproteomic and functional studies linked OR2L13 activation to HSP27 phosphorylation, actin cytoskeleton disorganization, impaired clot retraction, and marked suppression of arterial platelet accumulation.
- The preclinical profile is noteworthy because arterial thrombosis was reduced without detectable impairment of fibrin formation or baseline hemostasis in the reported models, a key translational differentiator from many conventional antiplatelet agents.
Background
Arterial thrombosis remains a major determinant of myocardial infarction, ischemic stroke, and complications after percutaneous or surgical revascularization. Contemporary antiplatelet therapy has improved outcomes substantially, yet residual ischemic risk persists in patients treated with aspirin, P2Y12 inhibitors, and, in selected settings, parenteral glycoprotein IIb/IIIa antagonists. Interindividual variability in platelet inhibition, drug nonresponsiveness, high residual platelet reactivity, competing bleeding risk, and pathway redundancy all limit the protective ceiling of current pharmacotherapy.
The major clinically validated platelet targets include cyclooxygenase-1, the ADP receptor P2Y12, protease-activated receptor-1, and the final common pathway integrin αIIbβ3. Landmark trials established the benefit of dual antiplatelet therapy in acute coronary syndromes and after coronary stenting, with more potent P2Y12 antagonists lowering ischemic events at the cost of increased bleeding in some populations. Even so, a sizable subgroup remains at high risk because platelets can still be activated through thrombin, collagen, thromboxane-independent signaling, shear-dependent mechanisms, and inflammatory crosstalk. This has motivated sustained interest in novel targets that may dissociate antithrombotic efficacy from hemostatic liability.
G protein-coupled receptors (GPCRs) are central regulators of platelet function. Beyond canonical platelet GPCRs, transcriptomic and proteomic studies have revealed unexpected expression of nontraditional receptor families in megakaryocytes and platelets, including receptors originally characterized in sensory biology. Olfactory receptors (ORs), classically studied in the olfactory epithelium, are now recognized as broadly expressed “ectopic” or “extranasal” GPCRs with functions in airway biology, metabolism, reproduction, cancer, smooth muscle biology, and immunity. However, their role in platelet physiology and thrombosis has remained poorly defined.
Aggarwal and colleagues now provide the strongest evidence to date that an orphan olfactory receptor can be pharmacologically engaged to inhibit platelet activation. Their work is clinically interesting not because it immediately changes practice, but because it opens an entirely new receptor class for antithrombotic drug development. The study is especially relevant to patients with high residual platelet reactivity, a longstanding challenge in coronary artery disease, peripheral artery disease, and post-infarction care.
Key Content
1. Why a new platelet target is needed
Residual ischemic risk despite guideline-directed antiplatelet therapy is a familiar clinical problem. Aspirin reduces thromboxane-mediated platelet activation but does not suppress ADP-, thrombin-, or collagen-mediated pathways. P2Y12 inhibitors are more potent, yet on-treatment platelet reactivity varies with genetic factors, absorption, drug interactions, comorbidity, and adherence. Clopidogrel hyporesponsiveness has been particularly well described, while more potent agents such as prasugrel and ticagrelor can improve ischemic protection but increase bleeding in selected patients.
Trials such as TRITON-TIMI 38 and PLATO redefined the field by showing that intensified P2Y12 inhibition can reduce major adverse cardiovascular events, but these gains were offset by clinically important bleeding trade-offs. This has led investigators to search for platelet signaling nodes that are more specific to pathologic thrombosis than to physiologic hemostasis. Emerging strategies have included glycoprotein VI blockade, factor XI/XIa inhibition, modulation of immunothrombosis, and now orphan GPCR targeting.
In that context, OR2L13 is conceptually attractive. If receptor activation preferentially weakens cytoskeletal remodeling, secretion, and thrombus stability under arterial flow, while sparing core coagulation and primary hemostatic responses, it could represent a mechanistically distinct antiplatelet class.
2. Biological rationale: extranasal olfactory receptors and platelet GPCR signaling
The modern view of olfactory receptors extends far beyond odor detection. ORs are seven-transmembrane GPCRs capable of coupling to diverse intracellular pathways depending on cell context. In nonolfactory tissues, OR activation has been linked to calcium flux, cyclic AMP signaling, kinase activation, migration, differentiation, and secretion. The platelet field has increasingly appreciated that receptor repertoires are broader than previously assumed, but most translational work has centered on conventional agonist receptors and immunoreceptors.
The 2026 study builds on earlier observations implicating OR family members in platelets, including the notion that some OR pathways may restrain rather than amplify activation. This is mechanistically important: unlike antagonism of prothrombotic receptors, agonism of an endogenous inhibitory pathway may provide a pharmacologic route to rebalance platelet reactivity.
OR2L13, an orphan receptor without a well-established endogenous ligand in platelet biology, was selected as the target. The authors used an engineered reporter platform expressing human OR2L13 and screened 8,000 nonodorant bioactive compounds. This approach is notable because it moves OR pharmacology away from volatile odorants and toward tractable medicinal chemistry relevant to cardiovascular drug development.
3. Study design and principal findings of Aggarwal et al. (Circulation 2026)
Aggarwal et al. performed a multiphase translational investigation spanning receptor discovery, platelet function testing, phosphoproteomics, biomechanics, and animal thrombosis models. Several design features strengthen the report:
- Targeted high-throughput screening: an OR2L13 reporter cell line was used to identify candidate agonists, followed by counterscreen validation for specificity.
- Human platelet validation: findings were tested in platelets from healthy individuals and from patients with coronary artery disease and peripheral artery disease.
- Mechanistic interrogation: phosphoproteomic mapping was used to identify downstream signaling mediators.
- Functional breadth: the authors evaluated aggregation, α-granule exocytosis, clot retraction, cytoskeletal organization, and in vivo thrombosis.
The screen yielded six OR2L13-specific agonists that suppressed platelet aggregation and α-granule exocytosis. The inhibition was observed across multiple receptor agonist pathways, suggesting convergence on a shared distal mechanism rather than simple blockade of a single proximal activation receptor.
The lead compound, CCF0054500, emerged as the principal probe. In platelets, it induced phosphorylation of HSP27 and disrupted actin cytoskeletal architecture. Functionally, this was associated with a dramatic reduction in clot retraction, with reported clot area values of 70.6 versus 5.2 (P<0.0001). Importantly, the effect was reversible with HSP27 inhibition, arguing that HSP27 is not merely an associated marker but a required downstream effector.
In vivo, the compound reduced platelet accumulation by 88.9% in a murine arterial injury model (P<0.0003), without affecting fibrin generation or hemostasis in the reported assays. In a myocardial infarction model characterized by high residual platelet reactivity, CCF0054500 reduced platelet reactivity (P<0.0001) and improved left ventricular function (P=0.007). Taken together, these findings support three linked claims: receptor-level specificity, mechanistic coherence, and preclinical antithrombotic efficacy.
4. Mechanistic synthesis: HSP27 and actin cytoskeleton remodeling as the antithrombotic axis
The mechanistic centerpiece of the paper is the connection between OR2L13 activation and HSP27-dependent actin remodeling. HSP27 is a small heat shock protein with established roles in cytoskeletal organization, stress signaling, actin polymerization dynamics, and cellular biomechanics. In platelets, shape change, secretion, spreading, clot contraction, and stable thrombus architecture all require finely tuned actin turnover and myosin-actin interactions.
This is an important departure from standard antiplatelet pharmacology. Aspirin modulates thromboxane synthesis; P2Y12 inhibitors alter cyclic AMP and signaling amplification; PAR antagonists interfere with thrombin receptor activation. By contrast, OR2L13 agonism appears to reprogram the structural machinery that allows platelets to convert receptor stimulation into biomechanical force generation. In practical terms, that means a platelet may still encounter agonists, but its ability to undergo full cytoskeletal rearrangement, secrete granule cargo efficiently, and retract a clot is reduced.
The clot retraction findings deserve particular attention. Clot retraction is a composite readout of outside-in integrin signaling, contractile cytoskeletal integrity, and thrombus compaction. Excessive clot retraction and thrombus contraction can promote occlusive arterial thrombi, alter red cell packing, and influence embolic properties. The profound reduction in clot retraction with CCF0054500 suggests that OR2L13-HSP27 signaling may preferentially destabilize the physical maturation of a platelet-rich thrombus rather than merely blunt initial aggregation.
From a translational standpoint, this cytoskeletal mechanism could explain the separation between reduced platelet accumulation and preserved fibrin generation. It hints at a therapeutic window in which pathologic platelet biomechanics are targeted while plasmatic coagulation remains intact.
5. Relation to the broader antiplatelet landscape
The novelty of OR2L13 agonism is best understood by comparing it with existing antithrombotic strategies.
Aspirin and P2Y12 inhibitors: These remain the foundation of therapy for acute coronary syndromes and post-PCI management. Their evidence base is extensive, but bleeding remains dose- and intensity-limiting, and on-treatment platelet reactivity persists in some patients.
PAR-1 antagonism: Vorapaxar validated thrombin receptor antagonism but at a significant bleeding cost, limiting routine uptake. The experience illustrates the difficulty of intensifying platelet inhibition through canonical pathways.
Integrin αIIbβ3 inhibition: Intravenous GP IIb/IIIa inhibitors are highly potent but carry bleeding and thrombocytopenia risk, confining them to select procedural or bailout settings.
Emerging “hemostasis-sparing” strategies: Glycoprotein VI inhibition and factor XI/XIa inhibition aim to preferentially affect thrombosis over hemostasis. OR2L13 agonism conceptually belongs to this same next-generation class, though it acts at the level of platelet structural signaling rather than collagen receptor biology or coagulation cascade amplification.
If future work confirms preserved bleeding profiles in humans, OR2L13-directed therapy could become part of a growing effort to uncouple arterial thrombosis prevention from hemorrhagic toxicity.
6. Translational relevance in coronary and peripheral artery disease
One of the stronger aspects of the study is the inclusion of platelets from patients with coronary artery disease and peripheral artery disease, rather than reliance on healthy donor samples alone. These populations often exhibit enhanced platelet activation, systemic inflammation, endothelial dysfunction, and variable pharmacologic responsiveness. Demonstrating inhibitory effects in disease-relevant human samples supports the possibility that OR2L13 agonism may work even in a milieu of heightened platelet priming.
The myocardial infarction model is also important. High residual platelet reactivity after infarction is associated with recurrent ischemic events and microvascular complications. The reported improvement in left ventricular function raises the possibility that reducing platelet-driven microvascular obstruction, inflammatory signaling, or recurrent microthrombosis could have downstream effects on remodeling. This remains speculative, but it is biologically plausible and increases the appeal of the platform.
In peripheral artery disease, platelet activation is often chronic and multifactorial, and ischemic event prevention must be balanced carefully against bleeding because many patients are elderly and comorbid. A cytoskeleton-focused platelet modulator with minimal hemostatic effect would be especially attractive in this group if clinical translation succeeds.
7. Strengths of the evidence
The study has several strengths that distinguish it from many receptor-discovery reports.
- End-to-end translational design: receptor screen to human platelet validation to animal thrombosis models.
- Mechanistic depth: phosphoproteomics and reversal by HSP27 inhibition support a specific downstream pathway.
- Disease relevance: testing in coronary and peripheral artery disease samples increases plausibility.
- Functional breadth: aggregation, secretion, cytoskeletal structure, and clot biomechanics were integrated rather than assessed in isolation.
- Thrombosis-hemostasis separation: the reported preservation of fibrin generation and hemostasis is a crucial translational signal.
8. Limitations and unresolved questions
Despite the excitement, this remains an early-phase, largely preclinical body of evidence, and several limitations should temper interpretation.
First, there are no human clinical outcome data. The work demonstrates ex vivo and in vivo preclinical efficacy but does not establish safety, pharmacokinetics, dose-response relationships, or bleeding risk in humans.
Second, the receptor biology remains incompletely resolved. ORs can display context-dependent signaling, promiscuity, and species differences. Whether OR2L13 has endogenous platelet ligands, how expression varies across individuals, and whether disease states alter receptor density or coupling remain unknown.
Third, drug development questions are substantial. The lead compound is a probe, not a clinically optimized therapeutic. Selectivity against the wider GPCRome, off-target sensory or nonhematologic effects, metabolic stability, oral bioavailability, and interaction with standard antiplatelet regimens all require study.
Fourth, the hemostasis-sparing signal requires rigorous confirmation. Animal bleeding assays are imperfect surrogates for human hemorrhagic risk. Many agents appear safe preclinically yet show mucosal, gastrointestinal, intracranial, or procedural bleeding liabilities in clinical trials.
Fifth, the long-term consequences of modulating platelet cytoskeletal function are uncertain. Platelets contribute not only to thrombosis but also to inflammation, wound healing, vascular integrity, host defense, and angiogenic signaling. Chronic OR2L13 activation may have effects beyond thrombosis prevention.
Finally, comparative positioning is undefined. It remains unclear whether OR2L13 agonists would be used as add-on therapy for patients with high residual platelet reactivity, as a substitute for conventional agents in bleeding-prone populations, or as short-term treatment during acute thrombotic syndromes.
Expert Commentary
This paper is best viewed as a landmark in target discovery rather than a practice-changing antiplatelet advance. Its significance lies in demonstrating that an orphan olfactory receptor expressed on platelets can be pharmacologically activated to produce robust antithrombotic effects through a defined downstream pathway involving HSP27 and actin remodeling. That is a conceptual breakthrough.
Clinically, the field has long sought antithrombotic approaches that preserve efficacy while reducing bleeding. Several lessons from prior decades are relevant. Intensifying inhibition of established pathways generally improves ischemic outcomes but increases hemorrhage. Conversely, strategies targeting thrombosis-specific mechanisms have had mixed success. OR2L13 agonism is compelling because it may act on the biomechanics of thrombus formation rather than on the earliest receptor-ligand events common to normal hemostasis.
The platelet cytoskeleton is an underexploited therapeutic space. Most clinicians think of platelet inhibition in terms of receptor antagonism or cyclooxygenase blockade; few currently conceptualize antithrombotic therapy as modulation of actin architecture and clot contraction. Yet the biomechanical phase of thrombosis is biologically central, particularly under high shear arterial conditions. If future studies validate that OR2L13-HSP27 signaling weakens thrombus propagation and consolidation more than primary hemostasis, this pathway could join glycoprotein VI and factor XI/XIa as part of a new generation of safer antithrombotic strategies.
That said, caution is warranted. The history of cardiovascular drug development is filled with mechanistically elegant preclinical discoveries that failed in human translation. Platelets are highly redundant, and effects observed under controlled conditions may be attenuated in the complex biochemical environment of acute coronary thrombosis. The receptor may also behave differently in humans with diabetes, chronic kidney disease, polypharmacy, and systemic inflammation.
Guideline implications are therefore premature. Current ACC/AHA and ESC antithrombotic frameworks remain anchored in aspirin, P2Y12 inhibition, and tailored antithrombotic intensification according to ischemic and bleeding risk. OR2L13 targeting does not yet belong in any clinical algorithm. However, it does suggest a future research agenda: identify endogenous ligands, define receptor expression across cardiovascular phenotypes, optimize medicinal chemistry, test combination effects with aspirin/P2Y12 inhibitors, and move into first-in-human pharmacodynamic studies.
A particularly interesting translational question is whether OR2L13 agonists could help patients with documented high residual platelet reactivity despite conventional therapy. This niche has been difficult to address because platelet function testing-guided escalation has not consistently translated into better outcomes. A mechanistically orthogonal add-on agent could be more effective than simply intensifying blockade within the same signaling family.
Conclusion
Aggarwal and colleagues report a highly innovative preclinical antiplatelet strategy centered on activation of the orphan platelet olfactory receptor OR2L13. Their data show that small-molecule OR2L13 agonists, especially CCF0054500, suppress platelet aggregation and α-granule secretion, trigger HSP27 phosphorylation, disrupt actin cytoskeletal organization, impair clot retraction, and markedly reduce arterial platelet accumulation in vivo. The preservation of fibrin generation and hemostasis in the reported models makes the platform particularly attractive.
For clinicians, the main message is not that practice should change today, but that platelet biology may be entering a new phase in which noncanonical GPCRs and thrombus biomechanics become therapeutically actionable. For translational scientists, the study provides a blueprint linking receptor discovery, phosphoproteomics, and disease-relevant thrombosis modeling. For drug developers, it identifies OR2L13-HSP27-actin signaling as a plausible route toward antithrombotic efficacy with a potentially improved safety profile.
The next steps are clear: reproducibility across laboratories, deeper receptor pharmacology, medicinal chemistry optimization, formal bleeding assessment, interaction studies with standard antiplatelet regimens, and early human trials. If these hurdles are overcome, OR2L13 agonism could become a genuinely new antiplatelet class for patients who remain at high ischemic risk despite current therapy.
Table: Positioning the 2026 OR2L13 study within the antiplatelet field
| Domain | Established therapies | OR2L13 agonism (2026 study) | Potential implication |
|---|---|---|---|
| Primary target | COX-1, P2Y12, PAR-1, αIIbβ3 | Orphan olfactory receptor GPCR (OR2L13) | New receptor class for platelet modulation |
| Mechanism | Blocks agonist generation or receptor signaling | Activates inhibitory signaling linked to HSP27 and actin remodeling | Biomechanics-focused thrombosis control |
| Main functional effects | Reduced aggregation/amplification | Reduced aggregation, α-granule exocytosis, clot retraction, platelet accumulation | May impair thrombus maturation and stability |
| Coagulation effect | Usually platelet-specific; some bleeding increase via impaired hemostasis | Reported no change in fibrin generation or hemostasis in preclinical assays | Possible thrombosis-hemostasis separation |
| Evidence stage | RCTs and guidelines | Preclinical and ex vivo human platelet data | Requires first-in-human development |
References
- Aggarwal A, Josyula VPVN, Wang N, Yang M, Shim YJ, Kennedy QP, Samuel R, Sangwan N, Guntupalli S, Godwin M, Park HE, Ali M, Jennings C, Rajasekar B, Scalise A, Sloan AR, Lathia JD, Grondolsky J, Schumacher SM, Stauffer S, McCrae KR, McIntyre TM, Cameron SJ. Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling. Circulation. 2026;153(23):1827-1844. PMID: 41944007.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057. PMID: 19717846.
- Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. PMID: 17982182.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339. PMID: 8918275.
- Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-1413. PMID: 22443427.
- Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31(1):17-28. PMID: 19897402.
- Ferreiro JL, Angiolillo DJ. High on-treatment platelet reactivity to adenosine diphosphate receptor antagonists in patients with coronary artery disease: clinical relevance and therapeutic options. J Am Coll Cardiol. 2011;58(1):1-10. PMID: 21700086.
- Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919-933. PMID: 20828644.
- Renne T, Grover SP, Ay C, Mackman N. The role of factor XI in venous and arterial thrombosis. Blood. 2023;141(1):16-27. PMID: 36112442.
- Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102(2):449-461. PMID: 12663456.
- Stellos K, Bigalke B, Langer H, Geisler T, Schad A, Kögel A, Pfaff F, Stakos D, Seizer P, Müller I, et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the degree of myocardial necrosis. Circ J. 2009;73(1):95-102. PMID: 19043276.
- Sun X, Wang J, Zhang J, Tu J, Wang XJ, Su XD. Heat shock protein 27 phosphorylation state regulates cell motility and actin cytoskeletal dynamics. J Biol Chem. 2007;282(9):6376-6385. PMID: 17158593.